Literature DB >> 19706538

Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels.

Ivica Grgic1, Eva Kiss, Brajesh P Kaistha, Christoph Busch, Michael Kloss, Julia Sautter, Anja Müller, Anuradha Kaistha, Claudia Schmidt, Girija Raman, Heike Wulff, Frank Strutz, Hermann-Josef Gröne, Ralf Köhler, Joachim Hoyer.   

Abstract

Proliferation of interstitial fibroblasts is a hallmark of progressive renal fibrosis commonly resulting in chronic kidney failure. The intermediate-conductance Ca(2+)-activated K(+) channel (K(Ca)3.1) has been proposed to promote mitogenesis in several cell types and contribute to disease states characterized by excessive proliferation. Here, we hypothesized that K(Ca)3.1 activity is pivotal for renal fibroblast proliferation and that deficiency or pharmacological blockade of K(Ca)3.1 suppresses development of renal fibrosis. We found that mitogenic stimulation up-regulated K(Ca)3.1 in murine renal fibroblasts via a MEK-dependent mechanism and that selective blockade of K(Ca)3.1 functions potently inhibited fibroblast proliferation by G(0)/G(1) arrest. Renal fibrosis induced by unilateral ureteral obstruction (UUO) in mice was paralleled by a robust up-regulation of K(Ca)3.1 in affected kidneys. Mice lacking K(Ca)3.1 (K(Ca)3.1(-/-)) showed a significant reduction in fibrotic marker expression, chronic tubulointerstitial damage, collagen deposition and alphaSMA(+) cells in kidneys after UUO, whereas functional renal parenchyma was better preserved. Pharmacological treatment with the selective K(Ca)3.1 blocker TRAM-34 similarly attenuated progression of UUO-induced renal fibrosis in wild-type mice and rats. In conclusion, our data demonstrate that K(Ca)3.1 is involved in renal fibroblast proliferation and fibrogenesis and suggest that K(Ca)3.1 may represent a therapeutic target for the treatment of fibrotic kidney disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19706538      PMCID: PMC2726862          DOI: 10.1073/pnas.0903458106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  52 in total

1.  Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia.

Authors:  Kenneth I Ataga; Wally R Smith; Laura M De Castro; Paul Swerdlow; Yogen Saunthararajah; Oswaldo Castro; Elliot Vichinsky; Abdullah Kutlar; Eugene P Orringer; Greg C Rigdon; Jonathan W Stocker
Journal:  Blood       Date:  2008-01-11       Impact factor: 22.113

Review 2.  Myofibroblast differentiation during fibrosis.

Authors:  A Desmoulière; G Gabbiani
Journal:  Exp Nephrol       Date:  1995 Mar-Apr

3.  Ras/MEK/ERK Up-regulation of the fibroblast KCa channel FIK is a common mechanism for basic fibroblast growth factor and transforming growth factor-beta suppression of myogenesis.

Authors:  T L Peña; S H Chen; S F Konieczny; S G Rane
Journal:  J Biol Chem       Date:  2000-05-05       Impact factor: 5.157

4.  The fibroblast intermediate conductance K(Ca) channel, FIK, as a prototype for the cell growth regulatory function of the IK channel family.

Authors:  T L Peña; S G Rane
Journal:  J Membr Biol       Date:  1999-12-01       Impact factor: 1.843

5.  Expression and function of endothelial Ca(2+)-activated K(+) channels in human mesenteric artery: A single-cell reverse transcriptase-polymerase chain reaction and electrophysiological study in situ.

Authors:  R Köhler; C Degenhardt; M Kühn; N Runkel; M Paul; J Hoyer
Journal:  Circ Res       Date:  2000-09-15       Impact factor: 17.367

6.  Endogenous hepatocyte growth factor ameliorates chronic renal injury by activating matrix degradation pathways.

Authors:  Y Liu; K Rajur; E Tolbert; L D Dworkin
Journal:  Kidney Int       Date:  2000-11       Impact factor: 10.612

7.  Basic fibroblast growth factor expression is increased in human renal fibrogenesis and may mediate autocrine fibroblast proliferation.

Authors:  F Strutz; M Zeisberg; B Hemmerlein; B Sattler; K Hummel; V Becker; G A Müller
Journal:  Kidney Int       Date:  2000-04       Impact factor: 10.612

8.  Local delivery of the KCa3.1 blocker, TRAM-34, prevents acute angioplasty-induced coronary smooth muscle phenotypic modulation and limits stenosis.

Authors:  D L Tharp; B R Wamhoff; H Wulff; G Raman; A Cheong; D K Bowles
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-02-28       Impact factor: 8.311

9.  Myofibroblasts differentiate from fibroblasts when plated at low density.

Authors:  S K Masur; H S Dewal; T T Dinh; I Erenburg; S Petridou
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

10.  Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+ channel, IKCa1: a potential immunosuppressant.

Authors:  H Wulff; M J Miller; W Hansel; S Grissmer; M D Cahalan; K G Chandy
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

View more
  78 in total

1.  KCa 3.1 channels maintain endothelium-dependent vasodilatation in isolated perfused kidneys of spontaneously hypertensive rats after chronic inhibition of NOS.

Authors:  Serge Simonet; Marc Isabelle; Mélanie Bousquenaud; Nicolas Clavreul; Michel Félétou; Christine Vayssettes-Courchay; Tony J Verbeuren
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

2.  Epithelial Notch signaling regulates interstitial fibrosis development in the kidneys of mice and humans.

Authors:  Bernhard Bielesz; Yasemin Sirin; Han Si; Thiruvur Niranjan; Antje Gruenwald; Seonho Ahn; Hideki Kato; James Pullman; Manfred Gessler; Volker H Haase; Katalin Susztak
Journal:  J Clin Invest       Date:  2010-10-18       Impact factor: 14.808

Review 3.  Evidence of K+ channel function in epithelial cell migration, proliferation, and repair.

Authors:  Alban Girault; Emmanuelle Brochiero
Journal:  Am J Physiol Cell Physiol       Date:  2013-11-06       Impact factor: 4.249

4.  Advanced glycation end products promote proliferation of cardiac fibroblasts by upregulation of KCa3.1 channels.

Authors:  Li-Mei Zhao; Wei Zhang; Li-Ping Wang; Gui-Rong Li; Xiu-Ling Deng
Journal:  Pflugers Arch       Date:  2012-10-02       Impact factor: 3.657

Review 5.  Physiological significance of delayed rectifier K(+) channels (Kv1.3) expressed in T lymphocytes and their pathological significance in chronic kidney disease.

Authors:  Itsuro Kazama
Journal:  J Physiol Sci       Date:  2014-08-06       Impact factor: 2.781

6.  The Lymphocyte Potassium Channels Kv1.3 and KCa3.1 as Targets for Immunosuppression.

Authors:  Jenny Lam; Heike Wulff
Journal:  Drug Dev Res       Date:  2011-11       Impact factor: 4.360

7.  Development of a QPatch automated electrophysiology assay for identifying KCa3.1 inhibitors and activators.

Authors:  David Paul Jenkins; Weifeng Yu; Brandon M Brown; Lars Damgaard Løjkner; Heike Wulff
Journal:  Assay Drug Dev Technol       Date:  2013 Nov-Dec       Impact factor: 1.738

8.  Involvement of dominant-negative spliced variants of the intermediate conductance Ca2+-activated K+ channel, K(Ca)3.1, in immune function of lymphoid cells.

Authors:  Susumu Ohya; Satomi Niwa; Ayano Yanagi; Yuka Fukuyo; Hisao Yamamura; Yuji Imaizumi
Journal:  J Biol Chem       Date:  2011-02-23       Impact factor: 5.157

9.  The potassium channel KCa3.1 as new therapeutic target for the prevention of obliterative airway disease.

Authors:  Xiaoqin Hua; Tobias Deuse; Yi-Je Chen; Heike Wulff; Mandy Stubbendorff; Ralf Köhler; Hiroto Miura; Florian Länger; Hermann Reichenspurner; Robert C Robbins; Sonja Schrepfer
Journal:  Transplantation       Date:  2013-01-27       Impact factor: 4.939

10.  Role of the K(Ca)3.1 K+ channel in auricular lymph node CD4+ T-lymphocyte function of the delayed-type hypersensitivity model.

Authors:  Susumu Ohya; Erina Nakamura; Sayuri Horiba; Hiroaki Kito; Miki Matsui; Hisao Yamamura; Yuji Imaizumi
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.